Diplomat Pharmacy, Inc. (NYSE:DPLO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Monday, July 17th.
According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “
DPLO has been the topic of several other reports. Mizuho upped their price target on Diplomat Pharmacy from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Tuesday, May 16th. BidaskClub lowered Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Thursday, June 29th. Bank of America Corporation upped their price target on Diplomat Pharmacy from $17.00 to $18.50 and gave the company a “neutral” rating in a research report on Thursday, May 25th. Cowen and Company increased their target price on Diplomat Pharmacy from $12.00 to $17.00 and gave the stock a “market perform” rating in a research report on Tuesday, May 9th. Finally, Barclays PLC set a $20.00 target price on Diplomat Pharmacy and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $20.91.
Diplomat Pharmacy (DPLO) opened at 15.41 on Monday. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of 61.39 and a beta of 0.63. Diplomat Pharmacy has a 12 month low of $12.25 and a 12 month high of $38.94. The stock’s 50 day moving average is $16.20 and its 200-day moving average is $15.59.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, May 8th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.04. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Diplomat Pharmacy had a return on equity of 7.91% and a net margin of 0.38%. The business’s revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.23 EPS. On average, equities research analysts expect that Diplomat Pharmacy will post $0.65 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://stocknewstimes.com/2017/07/30/diplomat-pharmacy-inc-nysedplo-cut-to-sell-at-zacks-investment-research-updated.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Highbridge Capital Management LLC acquired a new position in Diplomat Pharmacy during the fourth quarter valued at about $540,000. Teachers Advisors LLC boosted its position in Diplomat Pharmacy by 73.4% in the fourth quarter. Teachers Advisors LLC now owns 131,243 shares of the company’s stock valued at $1,654,000 after buying an additional 55,560 shares during the last quarter. Norges Bank acquired a new position in Diplomat Pharmacy during the fourth quarter valued at about $1,131,000. AQR Capital Management LLC boosted its position in Diplomat Pharmacy by 419.3% in the fourth quarter. AQR Capital Management LLC now owns 44,518 shares of the company’s stock valued at $561,000 after buying an additional 35,945 shares during the last quarter. Finally, Guggenheim Capital LLC acquired a new position in Diplomat Pharmacy during the fourth quarter valued at about $2,951,000. 72.27% of the stock is owned by institutional investors.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
